Abstract
Class I major histocompatibility complex (MHC) molecules function in the recognition of antigens by cytotoxic T lymphocytes (CTL)1,2. Although this biological role is firmly established and much has been learnt about their structure and polymorphic variation3–6, little is known of the regions of class I molecules that are involved in functional interactions with components of the T-cell surface. Here we show that peptides derived from residues 98–113 of the α2 domain of HLA–A2 specifically inhibit the recognition of target cells by many HLA–A2-specific CTL. In addition to identifying a region that is probably involved in binding the T-cell receptor these results raise the possibility that alloreactive CTL may recognize degraded fragments of class I histocompatibility antigens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zinkernagel, R. M. & Doherty, P. C. Adv. Immun. 27, 51–177 (1979).
Duran, L. W. & Pease, L. R. Transplantation 41, 279–285 (1986).
Nathenson, S. G., Geliebter, J., Pfaffenbach, G. M. & Zeff, R. A. A. Rev. Immun. 4, 471–502 (1986).
Lopez de Castro, J. A., Barbosa, J. A., Krangel, M. S., Biro, P. A. & Strominger, J. L. Immun. Rev. 85, 149–168 (1985).
Jordan, B. R. et al. Immun. Rev. 84, 73–92 (1985).
Lew, A. M. et al. Immunology 57, 3–18 (1986).
Townsend, A. R. M. & McMichael, A. J. in Progress in Allergy Vol. 36 (eds de Vries, R. R. P. & van Rood, J. J.) 10–43 (Karger, Basel, 1985).
Lindahl, K. F. & Bach, F. H. Nature 254, 607–609 (1975).
Nabholz, M. et al. Eur. J. Immun. 4, 378–387 (1974).
Townsend, A. R. M. et al. Cell 44, 959–968 (1986).
Biddison, W. E., Ward, F. E., Shearer, G. M. & Shaw, S. J. Immun. 124, 548–552 (1980).
Spits, H., Breuning, M., Ivanyi, P., Russo, C. & de Vries, J. E. Immunogenetics 16, 503–512 (1982).
Gaston, J. S. H., Rickinson, A. B. & Epstein, M. A. J. exp. Med. 158, 280–293 (1983).
Schulze, D. H. et al. Proc. natn. Acad. Sci. U.S.A. 80, 2007–2011 (1983).
Krangel, M. S., Taketani, S., Biddison, W. E., Strong, D. M. & Strominger, J. L. Biochemistry 21, 6313–6321 (1982).
Krangel, M. S., Biddison, W. E. & Strominger, J. L. J. Immun. 130, 1856–1862 (1983).
Cowan, E. P., Jordan, B. R. & Coligan, J. E. J. Immun. 135, 2835–2841 (1985).
Taketani, S., Krangel, M. S., Spits, H., de Vries, J. & Strominger, J. L. J. Immun. 133, 816–821 (1984).
Vega, M. A. et al. Proc. natn. Acad. Sci. U.S.A. 82, 7394–7398 (1985).
Ezquerra, A. et al. J. Immun. 137, 1642–1649 (1986).
Koller, B. H. & Orr, H. T. J. Immun. 134, 2727–2733 (1985).
Ways, J. P., Coppin, H. L. & Parham, P. J. biol. Chem. 260, 11924–11933 (1985).
Holmes, N. & Parham, P. EMBO J. 4, 2849–2854 (1985).
Clayberger, C. et al. J. exp. Med. 162, 1709–1714 (1985).
Auffray, C. & Novotny, J. Hum. Immun. 15, 381–390 (1986).
Pierschbacher, M. D. & Ruoslahti, E. Nature 309, 30–33 (1984).
Yamada, K. M., Kennedy, D. W. J. cell. Biochem. 28, 99–104 1985.
Krangel, M. S., Taketani, S., Pious, D. & Strominger, J. L. J. exp. Med. 157, 324–336 (1983).
Taketani, S., Krangel, M. S., Pious, D. & Strominger, J. L. J. Immun. 131, 2935–2938 (1983).
Dausset, J., Ivanyi, P. & Ivanyi, D. in Histocompatibilily Testing 1965 (eds, Balner, H., Cleton, F. L. & Eernisse, J. G.) 51–62 (Munksgaard, Copenhagen, 1965).
Ways, J. P. & Parham, P. Biochem. J. 216, 423–432 (1983).
Ways, J. P., Rothbard, J. B. & Parham, P. J. Immun. 137, 217–222 (1986).
Lancet, D., Parham, P. & Strominger, J. L. Proc. natn. Acad. Sci. U.S.A. 76, 3844–3848 (1979).
Parham, P., Androlewicz, M. J., Brodsky, F. M., Holmes, N. J. & Ways, J. P. J. immun. Meth. 53, 133–173 (1982).
Krangel, M. S., Orr, H. T. & Strominger, J. L. Cell 18, 979–991 (1979).
Lindahl, F. K. & Lemke, H. Eur. J. Immun. 9, 526–536 (1979).
Reiss, C. S. et al. Proc. natn. Acad. Sci. U.S.A 77, 5432–5436 (1980).
Erickson, B. W. & Merrifield, R. B. in: The Proteins Vol. 2, 3rd edn (eds Neurath, H. & Hill, R. L.) 255–527 (Academic, New York, 1970).
Wan, A. M., Ennis, P., Parham, P. & Holmes, N. J. Immun. 137, 3671–3674 (1986).
McMichael, A. J., Parham, P., Brodsky, F. M. & Pilch, J. R. J. exp. Med. 152, 195s–203s (1980).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Parham, P., Clayberger, C., Zorn, S. et al. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the α2 domain of HLA–A2. Nature 325, 625–628 (1987). https://doi.org/10.1038/325625a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/325625a0
This article is cited by
-
RDP1258, a New Rationally Designed Immunosuppressive Peptide, Prolongs Allograft Survival in Rats: Analysis of Its Mechanism of Action
Molecular Medicine (1999)
-
Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes
Nature Medicine (1996)
-
Molecular basis of transplant rejection and acceptance
Pediatric Nephrology (1991)
-
The structural basis of alloreactivity
Immunologic Research (1990)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
